How One Footballer’s Shin-Pad Allergen Was Identified
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured scene is an AI-created illustration of a fictional work, activity or research setting. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
The question behind this paper
This review looks at football equipment, foam materials and localized dermatitis. The aim is to preserve the study’s actual population, denominator, design and timepoint so a useful signal does not become a universal claim.
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | One young football player with severe shin-pad dermatitis plus 20 patch-test controls |
| Design | Clinical case report with high-performance liquid chromatography and aimed patch testing |
| Timepoint | Investigation after recurrent shin-pad exposure |
| Key result | Acetophenone azine was detected at about 20 µg/g in pad samples; the player reacted down to 0.001%, while 20 controls were negative at 0.01%. |
How to interpret the result
The analytic and patch-test alignment provides a strong case-level clue, not a population rate. It supports specialist investigation of the actual equipment rather than assumptions about all shin pads.
Important limitation: A single case cannot estimate frequency or prove risk across brands, and the substance’s function, metabolism, cross-reactions and optimal test preparation remained uncertain.
Questionnaires, examinations, patch tests, chemical analyses and trial models answer different questions. A positive screening result, symptom report or association can guide a next step, but it does not diagnose the cause of one person’s rash. Clinician-directed testing is interpreted alongside timing, distribution and verified exposures.
Questions to ask next
- What exactly was measured: reported symptoms, visible signs, allergy, work loss, performance or quality of life?
- Which denominator applies to the quoted percentage: everyone invited, respondents, symptomatic people, examined participants or a selectively tested subgroup?
- Did the design compare groups or follow change over time, and what factors could still explain the difference?
- Would occupational-health review, clinician examination or clinician-directed testing change the practical plan?
- What requires prompt medical evaluation, including rapidly spreading redness, drainage, fever, severe pain, breathing symptoms or major loss of function?
Primary and authoritative sources
- Primary medical research record: PubMed PMID 27198908
- Authoritative guidance relevant to this topic
- American Academy of Dermatology: eczema skin-care guidance
PubMed indexing is not NIH endorsement of a study’s interpretation, this article or any product.
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine and this article makes no treatment, cure, prevention, pediatric-safety or 24-hour claim.
Bottom line
The responsible conclusion is narrow: keep the population, denominator, comparator, timepoint and limitations attached, then use the evidence to ask better clinical and exposure-control questions rather than promise a universal result.